Epistemic Status: pretty confident, typical lit review.
This report was commissioned by one of my freelancing clients and published by permission.
Bacterial immunostimulants are safe and effective in preventing respiratory infections, cutting the risk of infection by 40-50%.
Antiseptic mouthwash and oral care cut the risk of respiratory infection in elderly or ventilator-bound patients by 50-60%, and may also have effects on healthy adults.
Probiotics probably reduce the duration, but not the incidence, of respiratory infections and improve immune function.
Alfa-interferon may reduce the risk or duration of colds, but causes nasal irritation and bleeding that may be more severe than the colds themselves.
Meditation, moderate exercise, and writing personal narratives may reduce the incidence or severity of respiratory tract infections and improve immune function. Spending time in forests and getting massages may improve immune function.
Echinacea and ginseng extracts have mixed and equivocal evidence of effectiveness at preventing respiratory tract infections.
Bacterial immunostimulants are used in Europe to prevent recurrent respiratory infections. These are made of lysed bacterial cells, and cause both a cellular and humoral immune response, making people more resilient to infections. A common bacterial immunostimulant, Broncho-Vaxom, can be ordered online, eg here. There are a large number of studies, of which the following are only a selection, confirming that immunostimulants significantly reduce the incidence of recurrent respiratory infections.
Broncho-Vaxom taken 10 consecutive days per month for three months, tested in a double-blind, placebo-controlled trial of 200 children in a Mexican girls’ orphanage, reduced the incidence of respiratory tract infections by 50%.
In a randomized controlled study of 357 elderly patients with chronic bronchitis, Broncho-Vaxom taken 10 consecutive days per month for three months decreased respiratory infections by 28%.
In a systematic review comprising 851 children, 32% of children treated with Broncho-Vaxom had at least 3 respiratory infections in a six-month period, compared to 58.2% of controls, p<0.001.
In a meta-analysis of 15 randomized trials comprising 2557 patients, polyvalent mechanical bacterial lysate (an extract of multiple bacteria) reduced the incidence of respiratory tract infections by 51%. These include studies on adults as well as children.
Cochrane’s review, comprising 36 placebo-controlled studies totaling 4060 children, finds that immunostimulants reduce the incidence of respiratory infections by 40% in susceptible children (those who have 3 or more respiratory infections a year.) Most trials indicated no adverse effects or low rates of adverse effects.
While most of the evidence on bacterial immunostimulants is in children or the elderly, the mechanism of action should be applicable to healthy adults as well, except that it may not have as large an effect if your immune system is stronger. They are safe and well-tolerated, and the evidence that they prevent respiratory infections in the populations studied is quite robust and consistent.
Using antiseptic mouthwash or even just gargling with water may prevent respiratory infections. There is a lot of evidence for this in the context of patients in the ICU or elderly people in nursing homes, whose oral hygiene is probably worse than the typical healthy adult, but mouthwash makes a large difference there. There are a few studies on healthy adults suggesting that oral care helps them as well. Chlorhexidine mouthwash is prescription-only; you can get it from your dentist if you have gingivitis.
Chlorhexidine gluconate mouthwash reduced respiratory tract infections in patients undergoing heart surgery by 69%.
The rate of nosocomial pneumonia in patients undergoing heart surgery was reduced by 52% in patients given chlorhexidine mouthwash.
A meta-analysis of randomized controlled trials of chlorhexidine gluconate mouthwash in patients on ventilators found that it reduced the risk of pneumonia by 47%.
Oral hygiene (help brushing after meals and regular visits to a dentist) reduced the incidence of pneumonia in nursing homes by 59%.
Gargling with water, in a study on 387 healthy adults, reduced the incidence of upper respiratory tract infections in a 1-month period by 36% compared to controls.
Alpha-interferon is a protein involved in the innate immune response against viral infection. Taken as a nasal spray, it can stimulate the immune system against respiratory infections. However, it also has side effects, such as nasal irritation and bleeding. Interferon is not prescribed as a preventative because of its side effects; however, it is sold online, e.g. here.
In a placebo-controlled study of 448 adults, intranasal alpha-interferon spray given at the onset of a cold in a family member significantly reduced the risk of colds. (1.3% of treated vs. 15.1% of placebo got colds within 2 weeks after spraying, p=0.003). Overall, this led to a 39% reduction in number of respiratory infections in the treatment group.
In a placebo-controlled study of 229 adults given intranasal alpha-interferon spray over six months, the treatment group got 41% fewer colds.
In a study of 304 adults given intranasal alpha-interferon or placebo, 8.5% of placebo-treated patients got a cold over a 22-day period compared to no interferon-treated. (p = 0.0002). However, the treatment group didn’t get fewer respiratory infections overall.
Low-dose interferon-alpha spray didn’t significantly reduce the incidence of respiratory infections in a randomized trial of 200 healthy adults. It did significantly reduce the incidence of moderate-to-severe symptoms in those who had serologically confirmed viral illnesses.
In a randomized trial of 220 subjects with confirmed colds, mucus was 66% less likely to contain cold viruses at day 5-7 in treated patients than controls, and the median duration of colds was significantly longer (9 days) in the placebo group than the treated group (6 days). Treated patients were significantly more likely to have blood in their mucus than placebo.
Probiotics, especially Lactobacillus and Bifidobacterium species (the kind found in yogurt) have been found to reduce the duration of respiratory tract infections, though not their incidence. Probiotics sometimes enhance immune parameters such as lymphocyte count and NK activity.
In a meta-study of 14 randomized controlled studies comprising 3451 participants, the pooled risk of having an upper respiratory tract infection when given a probiotic was 47% lower compared to placebo.
In a meta-study of 14 RCTs, ten out of the fourteen found no significant difference in incidence of respiratory tract infections between probiotic and placebo, but five out of six found significant reductions in symptom severity.
In a systematic review of 20 RCTs, probiotics significantly decreased the duration of respiratory tract infections (by about a day) and resulted in significantly fewer days absent from school/work due to respiratory tract infections.
In a Cochrane review of 12 RCTs, probiotics significantly reduced the duration and incidence of upper respiratory tract infections, in both children and adults; however, the quality of evidence was low.
In a study of 1072 elderly volunteers randomized to a fermented dairy product containing Lactobacillus casei or a control dairy product, treated patients had significantly shorter duration (by 4 days) of upper respiratory tract infection. 
In a study of 47 military recruits randomized either to a fermented dairy product containing Lactobacillus casei or a placebo dairy product, there was no difference in the incidence of respiratory infections.
In 30 healthy elderly subjects, Bifidobacterium lactis but not control significantly increased the number of lymphocytes and NK activity.
In a controlled study of 50 healthy Taiwanese subjects aged 40-81, Bifidobacterium lactis HN019 significantly increased NK and CD4+ activity over a period of 6 weeks, while milk alone did not.
In one study on 20 healthy subjects aged 40-65, Lactobacillus casei strain Shirota had no effect on immune parameters.
However, in a study of 30 elderly subjects, Lactobacillus casei strain Shirota caused significantly higher NK activity compared to placebo. 
And in a study of 20 subjects, both elderly and young, Lactobacillus casei strain Shirota caused significantly higher NK activity compared to baseline or placebo.
Fermented dairy products containing probiotics are safe and probably somewhat helpful for promoting recovery from respiratory infections.
It’s well known that psychological stress can weaken the immune system; stressful events like bereavement or studying for exams, as well as depression and anxiety disorders, increase susceptibility to infection. Some psychological interventions also reduce the risk of respiratory infections or have more indirect immune-stimulating effects. These include meditation, written emotional expression (writing about traumatic and emotional experiences in your own life), massage, and forest bathing (spending several hours walking mindfully in a forest.)
An 8-week mindfulness meditation course significantly increased (p < 0.05) antibody titers in response to a flu vaccine.
An 8-week meditation course reduced days of work lost to respiratory infections by 76% (p < 0.001) and global severity was significantly lower for meditation than control (p =0.004).
A guided relaxation exercise with imagery increased NK activity (p < 0.05) in an uncontrolled study on 10 healthy subjects.
In a randomized trial of 48 patients with HIV, those enrolled an 8-week mindfulness meditation course had significantly (p = 0.02) higher CD4+ T lymphocyte counts than patients in the placebo 1-day course.
In a trial of 28 patients with breast cancer randomized to either a 10-week mindfulness-based stress reduction class or no intervention, the treatment group had significantly more lymphocyte proliferation than the controls.
Written Emotional Expression
Written emotional expression — being prompted to write about “the most traumatic and emotional experiences of their lives” — for thirty minutes at a time for four consecutive days — in HIV patients raised their CD4 count gradually over a period of 6 months and instantly dropped their viral load, p=0.024 and p=0.035 respectively.
40 medical students randomly assigned to write about traumatic personal experiences or control topics for 4 consecutive daily sessions had significantly higher antibody titers in response to a hepatitis C vaccine.
In a study of 50 healthy undergraduates randomized to either writing about personal trauma or control topics for 4 consecutive daily sessions, those who wrote about trauma were significantly less likely to visit the health center for illness, and had stronger lymphocyte increases in response to mitogens.
Shinrinyoku, or “forest bathing” — a three-day trip to a forest, spending a total of 3 hours walking outside — increased NK counts significantly (p < 0.01) while a three-day city tourist visit did not.
Out of 12 male subjects taken on a 3-day “forest bathing” trip, 11 had significantly increased NK activity (by about 50%)
Back massages, but not progressive muscle relaxation therapy, significantly increased (p<0.05) CD4 count in adolescent girls with HIV.
Full-body massage in women undergoing radiation therapy for breast cancer significantly attenuated the drop in NK activity compared to controls.
Compared to light touch, Swedish massage significantly increased the number of lymphocytes in 53 healthy adults.
Compared to no massage, a month of daily massage significantly increased NK count, NK activity, and CD8 lymphocyte count in 29 gay men.
Moderate exercise can prevent respiratory tract infections and improve other measures of immune function. However, very intense exercise (as in marathon training) increases susceptibility to infection.
Cardiovascular exercise, but not flexibility exercise, prolonged seroprotection from the flu vaccine (increasing the percentage of subjects who were still protected at 24 weeks by 30-100%.) People in the flexibility group reported no more respiratory tract infections, but reported them as being less severe (p = 0.03).
An 8-week exercise course reduced sick days from respiratory infections by 52% (p = 0.042).
A program of treadmill exercise in elderly women significantly (p < 0.05) increased NK activity relative to sedentary controls.
An exercise program (brisk walking 5 times a week) significantly (p < 0.001) increased NK activity and cut the duration of respiratory infections in half compared to control in a study of 36 sedentary women.
Endurance athletes, compared to the rest of the population, experience more upper respiratory tract infections around training and competition. In non-athletes, higher rates of physical activity are associated with lower risk of upper respiratory tract infections.
Extract from Echinacea purpurea or Echinacea angustifolia (purple coneflower) reduces the incidence of respiratory infections in some but not all studies. The largest and most stringent meta-analyses have concluded that echinacea extracts don’t prevent respiratory infections, but it’s possible that some preparations are effective, more likely alcoholic extracts than pressed juice.
A meta-analysis comprising 1630 patients found that echinacea reduced the probability of a patient contracting a cold by 58%, p <0.001, and reduced the duration of colds by 1.4 days, p < 0.01.
A subsequent meta-analysis of 6 clinical studies comprising 2458 participants found that echinacea caused a 35.1% lower risk of recurrent respiratory tract infection than placebo. Alcoholic extracts reduced the risk of recurrent infections by 45%, while pressed juices did not have a significant effect.
A meta-analysis of 14 studies where subjects were experimentally infected with rhinovirus, comprising a total of 2040 patients, found that the likelihood of experiencing a clinical cold was 55% lower in patients treated with echinacea than controls, and the duration of a cold was 1.4 days lower with echinacea vs. placebo.
In a structured meta-analysis of 9 studies of echinacea on the common cold, the only two studies that met all criteria for high-quality experimental design was negative, while the other studies, which tended to have positive results, usually lacked proof of blinding.
In a Cochrane review of 24 double-blind trials comprising 4631 subjects found that echinacea extracts had no significant effect on preventing colds, though there were non-significant trends towards an effect.
A study of 430 young children randomized to echinacea, propolis and vitamin C extract or placebo for 12 weeks found a 50% reduction in the number of respiratory tract infections per child in the treatment group.
A randomized controlled study of 302 adults at military institutions or an industrial plant found no difference between echinacea ethanolic extract and placebo in the incidence of respiratory tract infections over a 12 week period.
In a randomized controlled study of 432 volunteers experimentally given rhinovirus, echinacea alcohol tincture had no effect on the incidence or severity of colds.
A randomized controlled trial of 128 adults given echinacea pressed juice or placebo at the onset of a cold found no significant difference in symptom severity or duration.
In a randomized controlled trial of 282 adults given echinacea tincture or placebo, symptom scores were 23% lower for echinacea than placebo.
In a randomized study of 524 children randomized to echinacea juice or placebo after getting a single respiratory infection, the treatment group was 24% less likely to get another respiratory infection over a 4-month observation period.
In a randomized controlled trial of 90 hospital staff members, those treated with echinacea did not significantly alter the risk of upper respiratory tract infections.
In a randomized study of 48 adults infected with the common cold and given echinacea pressed juice or placebo, echinacea did not significantly reduce incidence of colds.
In a randomized study of 719 adults with new-onset common colds, echinacea extract didn’t significantly reduce severity or duration.
In a randomized study of 755 subjects given either an alcohol extract of echinacea or placebo, the echinacea-treated patients had 21% fewer respiratory infections over a period of 4 months.
Echinacea extract is safe, and may have some effect on preventing respiratory infections, but the evidence is inconsistent and equivocal.
There are some studies providing positive evidence that ginseng reduces the incidense of respiratory infections, but the meta-studies show that overall its effects are non-significant.
A systematic review comprising 747 patients found that there was “insufficient evidence to conclude that ginseng reduces the incidence or severity of common colds” — there was a trend towards reduced incidence of colds, but this wasn’t statistically significant.
In a randomized study of 323 adults with a history of at least two colds in the past season given American ginseng (Panax quinquefolium) extract or placebo reduced the average number of colds per person in a four-month period by 27%, from 0.93 in the placebo group to 0.68 in the treated group.
In a randomized study of institutionalized elderly subjects treated with American ginseng extract or placebo, treated patients had 85% less chance of getting influenza (p < 0.033) and 89% less chance of getting any acute respiratory infection (p = 0.009).
In a study of 323 healthy volunteers randomized to COLD-FX (a ginseng extract) or placebo, there was no effect from the treatment on the number or duration of colds.
In a study of 783 adults treated with American ginseng extract or placebo, ginseng did not significantly affect the number of laboratory-confirmed respiratory infections.
Panax ginseng extract significantly (p < 0.001) increased NK cytotoxicity (a measure of immune function) over placebo.
Ginseng extract is safe and may have some immunostimulant activity, but there’s only weak evidence that it prevents respiratory infections.
Jara-Pérez, Jaime V., and Arturo Berber. “Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial.” Clinical therapeutics 22.6 (2000): 748-759.
Orcel, B., et al. “Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis.” European Respiratory Journal 7.3 (1994): 446-452.
Schaad, Urs B. “OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review.” World Journal of Pediatrics 6.1 (2010): 5-12.
Cazzola, Mario, Sreedhar Anapurapu, and Clive P. Page. “Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis.” Pulmonary pharmacology & therapeutics 25.1 (2012): 62-68.
Del‐Rio‐Navarro, Blanca Estela, et al. “Cochrane Review: Immunostimulants for preventing respiratory tract infection in children.” Evidence‐Based Child Health: A Cochrane Review Journal 7.2 (2012): 629-717.
DeRiso, Anthony J., et al. “Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery.” Chest 109.6 (1996): 1556-1561.
Houston, Susan, et al. “Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery.” American Journal of Critical Care 11.6 (2002): 567-570.
Tantipong, Hutsaya, et al. “Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution for the prevention of ventilator-associated pneumonia.” Infection Control & Hospital Epidemiology 29.2 (2008): 131-136.
Yoneyama, Takeyoshi, et al. “Oral care reduces pneumonia in older patients in nursing homes.” Journal of the American Geriatrics Society 50.3 (2002): 430-433.
Satomura, Kazunari, et al. “Prevention of upper respiratory tract infections by gargling: a randomized trial.” American journal of preventive medicine 29.4 (2005): 302-307.
Shah, Sachin A., et al. “Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis.” The Lancet infectious diseases 7.7 (2007): 473-480.
Schoop, Roland, et al. “Echinacea in the prevention of induced rhinovirus colds: a meta-analysis.” Clinical Therapeutics 28.2 (2006): 174-183.
Cohen, Herman A., et al. “Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study.” Archives of pediatrics & adolescent medicine 158.3 (2004): 217-221.
Melchart, Dieter, et al. “Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial.” Archives of Family Medicine 7.6 (1998): 541.
Turner, Ronald B., et al. “An evaluation of Echinacea angustifolia in experimental rhinovirus infections.” New England Journal of Medicine 353.4 (2005): 341-348.
Yale, Steven H., and Kejian Liu. “Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial.” Archives of internal medicine 164.11 (2004): 1237-1241.
Goel, V., et al. “Efficacy of a standardized echinacea preparation (EchinilinTM) for the treatment of the common cold: a randomized, double‐blind, placebo‐controlled trial.” Journal of clinical pharmacy and therapeutics 29.1 (2004): 75-83.
Weber, Wendy, et al. “Echinacea purpurea for prevention of upper respiratory tract infections in children.” Journal of Alternative & Complementary Medicine: Research on Paradigm, Practice, and Policy 11.6 (2005): 1021-1026.
O’neil, Joelle, et al. “Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial.” Annals of Allergy, Asthma & Immunology 100.4 (2008): 384-388.
Schapowal, Andreas, Peter Klein, and Sebastian L. Johnston. “Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials.” Advances in therapy 32.3 (2015): 187-200.
Sperber, Steven J., et al. “Echinacea purpurea for prevention of experimental rhinovirus colds.” Clinical Infectious Diseases38.10 (2004): 1367-1371.
Barrett, Bruce, et al. “Echinacea for Treating the Common ColdA Randomized Trial.” Annals of internal medicine 153.12 (2010): 769-777.
Caruso, Thomas J., and Jack M. Gwaltney Jr. “Treatment of the common cold with echinacea: a structured review.” Clinical Infectious Diseases 40.6 (2005): 807-810.
Jawad, Moutaz, et al. “Safety and efficacy profile of Echinacea purpurea to prevent common cold episodes: a randomized, double-blind, placebo-controlled trial.” Evidence-Based Complementary and Alternative Medicine 2012 (2012).
Melchart, D., et al. “Echinacea for preventing and treating the common cold.” Cochrane Database Syst Rev 2 (2000): CD000530.
Hayden, Frederick G., et al. “Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon.” New England Journal of Medicine 314.2 (1986): 71-75.
Douglas, Robert M., et al. “Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting.” New England Journal of Medicine 314.2 (1986): 65-70.
Farr, B. M., et al. “Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.” Antimicrobial agents and chemotherapy 26.1 (1984): 31-34.
Bennett, Alayne L., et al. “Low‐dose oral interferon alpha as prophylaxis against viral respiratory illness: a double‐blind, parallel controlled trial during an influenza pandemic year.” Influenza and other respiratory viruses 7.5 (2013): 854-862.
Hayden, FREDERICK G., D. L. Kaiser, and J. K. Albrecht. “Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.” Antimicrobial agents and chemotherapy 32.2 (1988): 224-230.
Seida, Jennifer Krebs, Tamara Durec, and Stefan Kuhle. “North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) preparations for prevention of the common cold in healthy adults: a systematic review.” Evidence-Based Complementary and Alternative Medicine 2011 (2011).
Predy, Gerald N., et al. “Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial.” Canadian Medical Association Journal 173.9 (2005): 1043-1048.
Mcelhaney, Janet E., et al. “A Placebo‐Controlled Trial of a Proprietary Extract of North American Ginseng (CVT‐E002) to Prevent Acute Respiratory Illness in Institutionalized Older Adults.” Journal of the American Geriatrics Society 52.1 (2004): 13-19.
Predy, Gerry N., et al. “Immune modulating effects of daily supplementation of COLD-fX (a proprietary extract of North American ginseng) in healthy adults.” Journal of Clinical Biochemistry and Nutrition 39.3 (2006): 162-167.
McElhaney, Janet E., et al. “Efficacy and Safety of CVT-E002, a proprietary extract of Panax quinquefolius in the prevention of respiratory infections in influenza-vaccinated community-dwelling adults: a multicenter, randomized, double-blind, and placebo-controlled trial.” Influenza research and treatment2011 (2011).
Scaglione, F., et al. “Immunomodulatory effects of two extracts of Panax ginseng CA Meyer.” Drugs under experimental and clinical research 16.10 (1990): 537-542.
Davidson, Richard J., et al. “Alterations in brain and immune function produced by mindfulness meditation.” Psychosomatic medicine 65.4 (2003): 564-570.
Barrett, Bruce, et al. “Meditation or exercise for preventing acute respiratory infection: a randomized controlled trial.” The Annals of Family Medicine 10.4 (2012): 337-346.
Zachariae, R., et al. “Effect of psychological intervention in the form of relaxation and guided imagery on cellular immune function in normal healthy subjects.” Psychotherapy and Psychosomatics 54.1 (1990): 32-39.
Creswell, J. David, et al. “Mindfulness meditation training effects on CD4+ T lymphocytes in HIV-1 infected adults: A small randomized controlled trial.” Brain, behavior, and immunity 23.2 (2009): 184-188.
McGregor, Bonnie A., et al. “Cognitive–behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer.” Journal of psychosomatic research 56.1 (2004): 1-8.
Petrie, Keith J., et al. “Effect of written emotional expression on immune function in patients with human immunodeficiency virus infection: a randomized trial.” Psychosomatic Medicine66.2 (2004): 272-275.
Petrie, Keith J., et al. “Disclosure of trauma and immune response to a hepatitis B vaccination program.” Journal of consulting and clinical psychology 63.5 (1995): 787.
Pennebaker, James W., Janice K. Kiecolt-Glaser, and Ronald Glaser. “Disclosure of traumas and immune function: health implications for psychotherapy.” Journal of consulting and clinical psychology 56.2 (1988): 239.
Li, Qing. “Effect of forest bathing trips on human immune function.” Environmental health and preventive medicine 15.1 (2010): 9-17.
Li, Q., et al. “Forest bathing enhances human natural killer activity and expression of anti-cancer proteins.” International journal of immunopathology and pharmacology 20.2_suppl (2007): 3-8.
Diego, Miguel A., et al. “HIV adolescents show improved immune function following massage therapy.” International Journal of Neuroscience 106.1-2 (2001): 35-45.
Billhult, A., et al. “The effect of massage on immune function and stress in women with breast cancer—a randomized controlled trial.” Autonomic Neuroscience 150.1 (2009): 111-115.
Rapaport, Mark Hyman, Pamela Schettler, and Catherine Bresee. “A preliminary study of the effects of a single session of Swedish massage on hypothalamic–pituitary–adrenal and immune function in normal individuals.” The Journal of Alternative and Complementary Medicine 16.10 (2010): 1079-1088.
Ironson, Gail, et al. “Massage therapy is associated with enhancement of the immune system’s cytotoxic capacity.” International Journal of Neuroscience 84.1-4 (1996): 205-217.
Woods, Jeffrey A., et al. “Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial.” Journal of the American Geriatrics Society 57.12 (2009): 2183-2191.
Crist, Douglas M., et al. “Physical exercise increases natural cellular-mediated tumor cytotoxicity in elderly women.” Gerontology 35.2-3 (1989): 66-71.
Nieman, D. C., et al. “The effects of moderate exercise training on natural killer cells and acute upper respiratory tract infections.” International journal of sports medicine 11.06 (1990): 467-473.
Moreira, André, et al. “Does exercise increase the risk of upper respiratory tract infections?.” British medical bulletin90.1 (2009): 111-131.
Hao, Qiukui, et al. “Probiotics for preventing acute upper respiratory tract infections.” Cochrane Database Syst Rev 9.9 (2011).
Vouloumanou, Evridiki K., et al. “Probiotics for the prevention of respiratory tract infections: a systematic review.” International journal of antimicrobial agents 34.3 (2009): 197-e1.
King, Sarah, et al. “Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis.” British Journal of Nutrition 112.1 (2014): 41-54.
Hao, Qiukui, Bi Rong Dong, and Taixiang Wu. “Probiotics for preventing acute upper respiratory tract infections.” The Cochrane Library (2015).
Guillemard, E., et al. “Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial.” British journal of nutrition103.1 (2010): 58-68.
Tiollier, Eve, et al. “Effect of a probiotics supplementation on respiratory infections and immune and hormonal parameters during intense military training.” Military medicine 172.9 (2007): 1006-1011.
Gill, Harsharnjit S., et al. “Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019.” The American journal of clinical nutrition 74.6 (2001): 833-839.
Chiang, Bor-Luen, et al. “Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses.” European journal of clinical nutrition 54.11 (2000): 849.
Spanhaak, S., R. Havenaar, and G. Schaafsma. “The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans.” European Journal of Clinical Nutrition 52.12 (1998): 899-907.
Dong, Honglin, et al. “Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers.” European journal of nutrition 52.8 (2013): 1853-1863.
Takeda, Kazuyoshi, and Ko Okumura. “Effects of a fermented milk drink containing Lactobacillus casei strain Shirota on the human NK-cell activity.” The Journal of nutrition 137.3 (2007): 791S-793S.